Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 91 of the 91 references it cites were found in a registry or an index; 16 of the 76 sources its claims cite were checked for support.

Physiologically Based Pharmacokinetic Modelling for First-In-Human Predictions: An Updated Model Building Strategy Illustrated with Challenging Industry Case Studies

Open access
Miller, Neil A., Reddy, Micaela B., Heikkinen, Aki T., Lukacova, Viera, Parrott, Neil · 2019 · Clinical Pharmacokinetics

Abstract

Physiologically based pharmacokinetic modelling is well established in the pharmaceutical industry and is accepted by regulatory agencies for the prediction of drug-drug interactions. However, physiologically based pharmacokinetic modelling is valuable to address a much wider range of pharmaceutical applications, and new regulatory impact is expected as its full power is leveraged. As one example, physiologically based pharmacokinetic modelling is already routinely used during drug discovery for in-vitro to in-vivo translation and pharmacokinetic modelling in preclinical species, and this leads to the application of verified models for first-in-human pharmacokinetic predictions. A consistent cross-industry strategy in this application area would increase confidence in the approach and facilitate further learning. With this in mind, this article aims to enhance a previously published first-in-human physiologically based pharmacokinetic model-building strategy. Based on the experience of scientists from multiple companies participating in the GastroPlus™ User Group Steering Committee, new Absorption, Distribution, Metabolism and Excretion knowledge is integrated and decision trees proposed for each essential component of a first-in-human prediction. We have reviewed many relevant scientific publications to identify new findings and highlight gaps that need to be addressed. Finally, four industry case studies for more challenging compounds illustrate and highlight key components of the strategy.

Overview

CoChat Summary

TL;DR

This review updates a previously published first-in-human (FIH) physiologically based pharmacokinetic (PBPK) model-building strategy by integrating new ADME knowledge, QSPR inputs, decision trees, and uncertainty analysis. Four challenging industry/literature case studies illustrate how measured inputs, preclinical verification, and parameter sensitivity analysis affect FIH predictions.

Key findings

  • The updated strategy emphasizes linking QSPR predictions with PBPK models before experimentation, using decision trees for elimination, distribution, oral absorption, and gut wall metabolism, and treating uncertainty/variability as central to FIH dose projection.
  • Compound 1 (neutral, clogP > 5, Fu < 0.1%, aqueous solubility < 1 µg/mL) used empirical rat-derived scaling factors; predicted human hepatic clearance was 0.5 mL/min/kg (range 0.2–0.7), observed systemic clearance was 0.18 mL/min/kg, predicted Vss was 3.2 L/kg versus observed 3.7 L/kg, and observed half-life was 10–14 days versus expected ~3 days.
  • Compound 2 showed blood/plasma ratio (BPR) as a critical input for a basic compound: predicted Vss was 3 L/kg with BPR = 0.91, 0.27 L/kg with BPR = 0.55, and 13.1 L/kg with BPR = 2; Vss was predicted within 60% of observed in all species except monkey (~3-fold error), and human Vss was ~20% overestimated.
  • Compound 3 (lipophilic weak acid) had human clearance predicted at 0.86–4.6 mL/min/kg and Vss explored from 0.48 to 3.6 L/kg; Compound 4 (high molecular weight > 1000 Da, BCS Class III, renal) used a rat-fitted specific PStc of 9.15 × 10⁻⁵ mL/s/mL cell volume, predicting urinary elimination of 69% within 24 h and 83% within 72 h versus observed 85% and 91%.

Methods

  • Design: a review and strategy update based on a comprehensive literature review and the combined experience of PBPK specialists from the GastroPlus User Group Steering Committee.
  • Data/sample: four case studies—Compounds 1–3 from industry predictions and Compound 4 based on literature data—selected to illustrate challenging compounds and key strategy components.
  • Analysis: simulations used GastroPlus and ADMETPredictor; the strategy incorporates QSPR plus PBPK assessment, ADME decision trees, preclinical model verification, parameter sensitivity analysis (PSA), and uncertainty/variability evaluation.

Limitations

  • Stated: the paper notes that a PhRMA evaluation did not find high PBPK prediction accuracy, especially for oral administration, but argues that analysis had severe limitations including diverse in-vitro assays, a bespoke platform, and no preclinical verification; it also cites OrBiTo findings that predictive performance declines with each layer of complexity and that uncertainty is higher for modellers with < 5 years’ experience.
  • Stated: several methodology gaps remain, including predicting clearance when transporters are involved, extrahepatic metabolism, enterohepatic circulation translation, improved Vss prediction when protein binding is too high to measure, validation of predicted tissue concentrations with transporters, and verification of intestinal metabolism for non-CYP3A4 gut enzymes.
  • Evident: the case studies are selected challenging examples rather than a systematic validation set, and some model adjustments are empirical or not yet fully established, such as BPR adjustment for phospholipid binding/lysosomal trapping, specific PStc prediction, and reliance on preclinical verification when IVIVE fails.

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.1007/s40262-019-00741-9

Cites

91 of 91 references verified0 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Verification

Claims the paper makes

15 Valid · 5 Not valid · 36 Not checked · 116 Own results and interpretations

85 more claims · 2 with their cited sources checked

Create a free account to see all 172 claims and to verify the 4 references still open.

See all claims — free account
  • It may state two separate claims as one. 55
  • Probably not a substantial claim. 38

Create a free account to see these claims.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 88 references

Research works printed but not linked: 2

  1. Teorell T. Kinetics of distribution of substances administered to the body. I. The extravascular modes of administration. Arch Int Pharmacodyn Ther. 1937;57:205–25.
  2. Nakashima M, Katagiri K, Oguma T. Phase I studies on vancomycin hydrochloride for injection. Chemotherapy. 1992;40(2):210–24.

Cited by

See all 142

Metadata

Authors
Miller, N. A., Reddy, M. B., Heikkinen, A. T., Lukacova, V., & Parrott, N.
Affiliations
  • GlaxoSmithKline (United Kingdom) (GB)
  • Array BioPharma (United States) (US)
  • F. Hoffmann-La Roche AG (CH)
Corresponding author
Miller, Neil A.
Venue
Clinical Pharmacokinetics
Published
2019-02-07
Volume
58
Issue
6
Pages
727-746
ISSN
  • 0312-5963 (ISSN-L)
  • 1179-1926
OpenAlex
W2912877386
Cited by
142
References
88
Citations by year
2026: 17 · 2025: 17 · 2024: 16 · 2023: 10 · 2022: 25 · 2021: 31 · 2020: 18 · 2019: 8
FWCI
4.32
Type
journal article
Language
en
Open access
Licence
  • cc-by-nc
  • creativecommons.org/licenses/by-nc/4.0 (tdm)
Locations
  • Clinical Pharmacokinetics (publishedVersion, cc-by-nc)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Pediatrics, Perinatology and Child Health › Pharmaceutical studies and practices
  • Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmacology › Pharmacogenetics and Drug Metabolism
  • Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Drug Discovery › Computational Drug Discovery Methods
Keywords
physiologically based pharmacokinetic modelling, model building strategy, ADME, in vitro to in vivo translation, drug-drug interactions, GastroPlus, decision tree, industry case studies
MeSH terms
Computer Simulation, Drug Industry, Pharmaceutical Preparations, Humans, Metabolic Clearance Rate, Models, Biological, Pharmacokinetics, Tissue Distribution, Quantitative Structure-Activity Relationship, Drug Discovery, Absorption, Physiological

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

The claim verdicts this report counts are experimental: their accuracy is not yet measured.

A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Cited sources are checked with a language model’s help (gpt-6-sol).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Physiologically Based Pharmacokinetic Modelling for First-In-Human Predictions: An Updated Model Building Strategy Illustrated with Challenging Industry Case Studies. https://app.cochat.ai/papers/10.1007/s40262-019-00741-9
The paper
Miller, N. A., Reddy, M. B., Heikkinen, A. T., Lukacova, V., & Parrott, N. (2019). Physiologically Based Pharmacokinetic Modelling for First-In-Human Predictions: An Updated Model Building Strategy Illustrated with Challenging Industry Case Studies. Clinical Pharmacokinetics. https://doi.org/10.1007/s40262-019-00741-9

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.